AUSTIN, Texas--(BUSINESS WIRE)--Babson Diagnostics, a science-first healthcare technology company, today announced its laboratory has been awarded accreditation by the College of American Pathologists (CAP) based on the results of a recent site inspection.
CAP is a leading healthcare accreditation agency, known for its comprehensive and scientifically rigorous standards. Babson’s compliance means the company is meeting the highest standards of quality and patient safety in its laboratory practices.
Babson’s lab in Austin first received CAP accreditation in 2020. In the renewal application, Babson for the first time demonstrated proficiency for its proprietary testing techniques, a critical innovation in its unique end-to-end technological ecosystem that reimagines blood testing for today’s consumer. Babson built its high-efficiency lab to run broad blood panels using one-tenth the sample volume of traditional blood tests. The company has developed miniaturized assays to optimize each microsample.
“We thank the Accreditation Committee of the College of American Pathologists for its thorough review,” said James Jacobson, Ph.D., vice president of clinical affairs at Babson. “Receiving accreditation reflects our commitment to a rigorous scientific evaluation of our innovative analysis technologies before commercialization of the Babson blood-testing system.”
The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal to or more stringent than the government's own inspection program.
During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory's records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.
“On our journey to make routine blood testing easier, more accessible, and less invasive, we are innovating with integrity,” said David Stein, Ph.D., Babson's chief executive officer. “Achieving accreditation is another step in our plan to show that our unique ecosystem meets high scientific standards and produces quality diagnostic results that patients and providers can rely on.”
About the College of American Pathologists
As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, visit https://www.cap.org.
About Babson Diagnostics
Babson Diagnostics is a healthcare technology company rooted in science reimagining the entire diagnostic blood testing experience. Babson’s mission is to make routine blood testing less invasive, more convenient and affordable, empowering people to take charge of their health.
Babson will bring medically accurate blood testing to the retail pharmacy by using patented technologies and a first-of-its-kind ecosystem that requires only one-tenth the sample volume of traditional venipuncture methods without sacrificing quality, accuracy, or menu breadth.
The company has received key patents in the United States, European Union, and China related to its unique end-to-end technological ecosystem and the ability to maximize the clinical utility of microsamples of blood collected from a fingertip. In addition, Babson has fully validated a broad set of miniaturized assays that are ready for commercial use in its CLIA-certified laboratory.
Babson, based in Austin, Texas, was founded by individuals with deep experience in healthcare, diagnostics, engineering, and laboratory technologies. It is named in honor of Art Babson, whose legacy of scientific innovation and excellence is the foundation on which the company is built.